K2M GROUP HOLDINGS, INC. (NASDAQ:KTWO) Files An 8-K Submission of Matters to a Vote of Security Holders
Item 5.07 Submission of Matters to a Vote of Security Holders.
Company) was held on June 6, 2017. The final voting results on each
of the matters submitted to a vote of the Companys shareholders at
the Annual Meeting are set forth below:
of Directors for terms ending in 2020. The shareholders elected
each of the nominees to the Board of Directors with the following
votes:
|
Director
|
|
Votes For
|
|
Votes Against
|
|
Withheld
|
|
Broker Non-Votes
|
|
Daniel Pelak
|
|
19,549,559
|
|
|
|
14,156,932
|
|
3,537,724
|
|
Carlos A. Ferrer
|
|
20,326,622
|
|
|
|
13,379,869
|
|
3,537,724
|
Companys independent registered public accounting firm for the
fiscal year ended December 31, 2017. The proposal was approved and
received the following votes:
|
Votes For
|
|
Votes Against
|
|
Abstentions
|
|
Broker Non-Votes
|
|
37,243,270
|
|
|
|
|
|
|
forward-looking statements within the meaning of the federal
securities laws. Forward-looking statements are based on
management’s expectations, estimates, projections, and
assumptions. These statements are not guarantees of future
performance and involve certain risks and uncertainties, which are
difficult to predict. Therefore, actual future results and trends
may differ materially from what is forecast in forward-looking
statements due to a variety of factors. Additional information
regarding these factors is contained in the sections entitled Risk
Factors and Management Discussion and Analysis of Financial
Condition and Results of Operations included in our Annual Report
on Form 10-K for the year-ended December 31, 2016, as updated by
our periodic filings with the SEC, accessible on the SEC’s website
at www.sec.gov.
About K2M GROUP HOLDINGS, INC. (NASDAQ:KTWO)
K2M Group Holdings, Inc. is a medical device company focused on designing, developing and commercializing spine technologies and techniques. The Company’s spine products are used by spine surgeons to treat spinal pathologies, such as deformity (primarily scoliosis), trauma and tumor. The Company is engaged in designing, development and commercialization of products for patients suffering from degenerative spinal conditions. Its products consist of implants, disposables and instruments, which are marketed and sold primarily to hospitals for use by spine surgeons. The Company’s product portfolio contains over 70 product lines that are used in spine surgeries, minimally invasive spine (MIS) and degenerative surgeries. It markets or sells its products in the United States and over 36 other countries. The Company’s technologies include MESA, Rail 4D, Quicket Deformity, CAPRI, SERENGETI, RAVINE, EVEREST, CASCADIA and tifix.
